EDIT - Editas Medicine GAAP EPS of -$0.88 misses by $0.08 revenue of $6.54M beats by $2.78M
- Editas Medicine press release ( NASDAQ: EDIT ): Q4 GAAP EPS of -$0.88 misses by $0.08 .
- Revenue of $6.54M (-47.6% Y/Y) beats by $2.78M .
- Collaboration and other research and development revenues decreased by $6.0 million to $6.5 million for the three months ended December 31, 2022, compared to $12.5 million for the same period in 2021. The decrease was primarily attributable to a decrease in collaboration related milestones.
- Cash, cash equivalents, and marketable securities as of December 31, 2022, were $437.4 million. The Company expects that its existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2025.
For further details see:
Editas Medicine GAAP EPS of -$0.88 misses by $0.08, revenue of $6.54M beats by $2.78M